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INTRODUCTION 
Hematopoiesis  is  the  process  by  which  the  formed  elements  
of  the  blood  are  formed.  The  process  is  regulated  through  a  series  
of  steps  beginning  with  the  pluripotent  hematopoitic  stem  cell.  Stem  
cells  are  capable  of  producing  red  cells,  all  classes  of  granulocytes,  
monocytes,  platelets,  and  the  cells  of  the  immune  system.1 
An  introduction  to  the  liver  cannot  go  without  mentioning  
that  it  is  the  largest  organ  of  the  body,  weighing  about  1  to  1.5  
kg,  and  representing  1.5 - 2.5  %  of  the  lean  body  mass.  Liver  is  
located  in  the  right  upper  quadrant  of  the  abdomen.  It  receives  dual   
blood  supply;  20%  from  the  hepatic  artery  and  80%  from  the  
portal  vein.  Physiologically,  the  majority  of  cells  in  the  liver  are   
the  hepatocytes  ( 2/3rds );  the  remaining  cells  are  the  Kupffer  cells,   
stellate  cells,  endothelial  cells,  blood  vessels,  bile  ductular  cells  and  
supporting  structures.2  
The  relationship  between  the  hematopoietic  system  and  the  
hepatic  system  in  the  human  body  dates  back  to  the  intrauterine  
period  where  the  latter  acts  as  a  haemotopoietic  organ  and  
functions   as  the  producer  of  the  former.   
Hepatocytes  perform  numerous  and  vital  roles  in  maintaining  
homeostasis.  These  functions  include  synthesis  of  essential  serum  
proteins ( albumin,  carrier  proteins,  coagulation  factors ),  the  
 2
production  of  bile  and  its  carriers,  the  regulation  of  nutrients  like  
lipids,  cholesterol,  glucose ).2  Albumin  and  other  carrier  proteins  
have  a  role  in  homeostasis.  Globulin  is  required  in  the  synthesis  of  
heamoglobin.  The  coagulation  factors  produced  by  the  liver  play  
important  roles  in  preventing  a  tilt  in  the  precarious  balance  held  
between  bleeding  and  thrombosis.  Bilirubin  is  a  by-product  of  heme  
breakdown.  Nutrients  like  cholesterol  and  lipids  are  needed  in  the  
synthesis  of  the  blood  cells.  From  the  above  information,  it  is  not  
difficult  to  see  the  inter-relationship  between  the  hepatic  and  the  
hematopoietic  systems.   
It  is  known  that  the  hormone  Erythropoietin  is  required  for  
red  cell  production.  Erythropoietin  is  not  only  produced  by  the  
peritubular  capillary  lining  cells  in  the  kidney,  it  is  also  produced  
by  hepatocytes.1  Liver  is  the  storage  site  for  iron,  vitamin  B12  and   
folic  acid  which  are  necessary  for  normal  hematopoiesis.3,4 
It  is  now  understood  chronic  liver  disease  presents  with  
haemotological  abnormalities.  It  is  worth  mentioning  that  other  than  
liver  disease  per  se,  the  complications  following  chronic  liver  
disease  contribute  to  haemotological  disturbances.  Such  
complications  include    G.I  bleed  secondary  to  portal  hypertension,  
hyperspenism,  hemolysis  and  malnutrition.5   
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It  is  not  unknown  to  clinicians  that  the  routine  liver  function  
tests  always  incorporate  serum  bilirubin,  serum  albumin  and  
prothrombin  time.  As  mentioned  above,  derangements  in  the  values  
of  the  above  parameters  gives  us  an  idea  of  the  disturbances  in  the  
haemotopoietic  system.  When  the  liver  is  damaged  by  either  acute   
or  chronic  disease,  abnormalities  in  the  haemotopoietic  system  
follow  suit.   
The  hematological  abnormalities  in  a  chronic  liver  disease  add  
morbidity  to  the  primary  pathology  and  increase  the  mortality.    
Hence  it  becomes imperative  to  investigate  the  hematological   
abnormalities  to  decrease  the  co-morbidity.        
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AIM OF THE STUDY 
1. To  identify  the  various  hematological  abnormalities  in   patients  
with  decompensated  chronic  liver  disease .  
2. To  find  out  the  prevalence  of  these  haemotological   abnormalities  
within  the  study  group. 
3. To  identify  whether  certain  haemotological  abnormalities  are  
more  associated  with  chronic  liver  disease  patients.  
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REVIEW OF LITERATURE 
LIVER  
The  anatomical  and  physiological  aspects  of  the  liver  have  
already  been  reviewed  earlier.  Pathological  disease  of  the  liver  can  
be  either  acute  or  chronic.  Chronic  liver  disease  is  characterized  by  
cirrhosis.  Cirrhosis  of  liver  is  defined  histopathologically;  it  consists  
of  the  development  of  fibrosis  to  the  point  that  there  is  
architectural  distortion  with  the  formation  of  regenerative  nodules.6  
This  results  in  loss  of  hepatic  mass  and  function  with  an  alteration  
in  blood  flow.  The  induction  of  fibrosis  occurs  with  activation  of  
hepatic  stellate  cells.6  
Clinically,  such  patients  with  cirrhosis  of  liver  can  present  in  
a  compensated  or  decompensated  form. 
                        Table – 1 –Some  Causes  of  Cirrhosis6 
Alcoholism                            Cardiac Cirrhosis        NASH 
Chronic Viral Hepatitis       Hemochromatosis       A1 AT Deficiency 
Autoimmune hepatitis         Wilson’s disease         Cystic Fibosis      
 
COMPENSATED CIRRHOSIS7  
Compensated cirrhosis  is discovered  at  routine  examination  or  
biochemical   analysis  with or  without  external  signs  and  symptoms  
of  liver  failure. They may present with   nausea,  vomiting,  indigestion,  
flatulence  or dyspepsia.   It  may  be  suspected  in  patients  with   spider 
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angiomas,  palmar  erythema,  unexplained  epistaxis  or  edema  of  
ankles.  
Clinically  firm  enlargement  of  liver  and  Splenomegaly  may  be   
present.  There  may  be  a  slight  increase  in  serum  transaminase  or   
γ Glutamyl  Transferase  level7.  
DECOMPENSATED  CIRRHOSIS  
Patients  who  have  developed  complications  of  cirrhosis  are  
said  to  have  decompensated  liver  disease.6  Signs  of  liver  cell  failure  
like  ascites  and  jaundice  are  present   in  patients  with  
Decompensated  liver  disease. 
                   Table 2 - Complications of Cirrhosis6 
Portal hypertension                             Hepatopulmonary syndrome 
Variceal bleed                                      Malnutrition 
Splenomegaly and hypersplenism    Coagulopathy 
Ascites and SBP                                   Bone disease 
Hepatorenal syndrome                        
Hematological abnormalities; anemia, hemolysis, thrombocytopenia, 
neutropenia 
Hepatic Encephalopathy 
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HAEMATOLOGICAL  ABNORMALITIES  AND  CHRONIC  
LIVER  DISEASE  -  REVIEW  OF  PREVIOUS  LITERATURE 
I ) DISORDERS  OF  RBC   
ANAEMIA 
 Anaemia  of  diverse  etiology  occurs  in  75%  of  patients  with  
chronic  liver  disease.8  The  causes  of  anaemia  can  be  studied  under  
various  etiologies : 
1. Portal  Hypertension    
Acute  gastrointestinal  hemorrhage  is  a  common  and  
potentially   serious  complication  of  portal  hypertension9,10,11,12.  It  is  
usually   caused  by  rupture  of  an  esophageal  varix.  Hemorrhage  
caused  by   this  mechanism  is  the  second  most  common  cause  of  
mortality  in   patients  with  cirrhosis.  In  such  patients,  a  ruptured  
esophageal  varix   is  the  cause  of  approximately  70%  of  episodes  of  
upper   gastrointestinal  hemorrhage10.  Acute  hemorrhage  may  induce  
severe  hypovolemia  and  subsequently  secondary  iron  deficiency  
anemia.   
The  initial  aim  of  treatment  is  correction  of  hypovolemia  and   
restoration  of  stable  hemodynamic  function;  minimal  values  for   
mean  arterial  pressure  and  for  haemoglobin  of  80  mmHg  and  8 
g/100 mL,  respectively,  should  be  maintained.  Initially,  gelatin-based   
colloids  or  solutions  of  human  albumin  may  be  infused  to  correct  
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hypovolemia.  However,  infusions  of  packed  erythrocytes  in  plasma  
are  ideal  in  this  context  since  such  infusions  have  the  potential  of   
correcting,  not  only  hypovolemia,  but  also  secondary  anemia.  First-
line  management  involves  institution  of  medical  therapy;  
administration  of  vasoactive  drugs,  such  as  somatostatin,  octreotide   
or  terlipressin;  and  optimal  endoscopic  treatment  involves  ligation  of  
esophageal  varices  and  obturation  of  gastric  varices  with  tissue  
adhesives.   
In  some  patients  with  cirrhosis,  chronic  hemorrhage  into  the  
gastrointestinal  tract  occurs.  Esophageal,  gastric  varices  and  portal  
hypertensive  gastropathy  may  be   associated  with  slow  chronic  loss  
of  blood  into  the  gut  and   development  of  chronic  iron  deficiency  
anemia.   
The  most  important   approach  to  management  is  prevention  of  
variceal  hemorrhage9,11,12.  The  annual  incidence  of  initial  variceal   
hemorrhage  in  patients  with  cirrhosis  is  estimated  to  be  about  4%,   
but  for  the  group  with  medium-sized  or  large   varices,  the  incidence  
is  about  15%10.  β-blockers  or  isosorbide  5-mononitrate  may  reduce  
the  rate  of  transformation  of  small  varices  into  large  varices  and  
decrease  the  incidence  of  variceal  hemorrhage   in  patients  with  
small  varices9.   
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The  risk  of  recurrent  hemorrhage   is  > 60%.  Accordingly,  all  
patients  surviving  variceal  hemorrhage   should  receive  active  
treatment  aimed  at  preventing  recurrence.   Nonselective  β-blockers  
or  isosorbide  5-mononitrate  and  endoscopic   therapy,  including  
ligation  of  and/or  sclerotherapy  of  varices,  are  the  first-line  
treatments  for  preventing  recurrence  of  variceal   hemorrhage9,12;  a  
combination  of  both  these  approaches  constitutes  optimal  
management.   
Additional  treatment  with  oral  iron   supplementation  is  
indicated  for  iron  deficiency  anemia  caused  by  chronic  blood  loss.  
In  some  cases  of  advanced  chronic  liver  disease,  intravenous  iron  
formulations  may  be  administrated  to   increase  plasma  levels  and  
tissue  deposits  of  iron.   
2. Hypersplenism 
Hypersplenism  secondary  to  portal  hypertension  is  another   
mechanism  of  anemia  in  patients  with  chronic  liver  disease.  
Hypersplenism  is  associated  with  splenomegaly.  In  addition  to   
chronic  liver  disease,  thrombosis  of  the  splenic  vein  may  also  be  a   
cause  of  an  increase  in  pressure  within  the  portal  venous  system,   
which  can  lead  to  secondary  hypersplenism.   
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The  main  characteristics  of  hypersplenism  are  those  
attributable  to  pancytopenia.  Hemolytic  anemia  occurs  because  of  
intrasplenic   destruction  of  erythrocytes.  Destruction  of  
megakaryocytes  and   leukocyte  precursors  results  in  
thrombocytopenia  and  leukopenia13.    
Symptoms  and  signs  of  hypersplenism  are  influenced  by  the  
primary underlying  disease;  they  include  abdominal  pain  and/or  
discomfort,  and,  in  advanced  cases,  gastrointestinal  hemorrhage   
secondary  to  portal  hypertension.  There  may  be  hyperplasia  of  the   
progenitor  cells  in  the  bone  marrow.   
It  is  important  to  determine   the  cause  of  hypersplenism.  The  
main  therapeutic  approach  for  this  syndrome  is  management  directed  
at  the  underlying  primary  disease,   usually  chronic  liver  disease.  
When  chronic  liver  disease  is   advanced,  additional  therapeutic  
options  may  need  to  be  adopted.   After  assessing  the  severity  of  
impaired  hepatocellular  function  in  a   patient  with  advanced  chronic  
liver  disease,  splenectomy  may  be   considered  if  the  splenic  vein  is  
thrombosed.  An  alternative   approach  is  partial  or  total  embolization  
of  the  splenic  artery,   which,  in  some  recent  studies,  has  been  
associated  with  good   results,  in  particular,  lower  morbidity  and  
mortality  rates  than  those  associated  with  surgery.  Partial  
embolization  preserves  the   immunological  function  of  the  spleen  
and  is  the  preferred  option   for  patients  with  cirrhosis14.   
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3. Aplastic Anaemia 
Aplastic  anemia  associated  with  liver  disease  is  characterized  
by   development  of  pancytopenia  and  hypocellular  bone  marrow  in   
relation  to  the  occurrence  of  hepatitis15.  The  main  feature  of  this   
syndrome  is  injury  to  or  loss  of  pluripotent  hematopoietic  stem  
cells,  in  the  absence  of  infiltrative  disease  of  the  bone  
marrow15,16,17,18.  Hepatitis-associated  aplastic  anemia  (HAA)  has  been  
defined  as   a  variant  of  aplastic  anemia,  which  occurs  concurrently  
with  or   within  6  months  of  an  increase  in  the  serum  level  of  
alanine   aminotransferase  to  at  least  five  times  the  upper  limit  of  
the   reference  range.   
Severe  marrow  aplasia  may  be  induced  by  hepatitis   viruses,  
such  as  hepatitis  B  virus  and  hepatitis  C  virus  (HCV),  and  also  by  
other  viruses,  such  as  human  immunodeficiency  virus,   Epstein-Barr  
virus,  transfusion-transmitted  virus  and  echovirus15,19.   Parvovirus  
B19  commonly  infects  pro-erythroblasts  and  may  induce   transient  
red –cell  aplasia,  particularly  in  patients  with  chronic   haemolytic  
anemia.  It  has  been  postulated  that  viruses  and/or  antigens,  through  
the  mediation  of  γ  interferon  or  the  cytokine  cascade,  induce  
lymphocyte  activation  and  ultimately  apoptotic  death   of  
hematopoietic  cells  in  the  bone  marrow16.   
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Clinical  presentation   includes  symptoms  and  signs  related  to  
pancytopenia,  such  as   pallor,  fatigue,  hemorrhagic  manifestations,  
progressive  anemia,  and   bacterial  infections.   
The  diagnosis  of  HAA  is  suggested  by  a   complete  blood  
count,  which  reveals  pancytopenia  (including  anemia)  together  with  
absolute  reticulocytopenia15.  A  bone  marrow  biopsy  typically  reveals  
hypocellularity  that  affects  red  and   white  cell  precursors  and  
megakaryocytes;  residual  hematopoietic  cells  appear  morphologically  
normal18.   
The  two  major  options  for   treating  severe  HAA  are  
hematopoietic  cell  transplantation  and   immunosuppressive  therapy.  
According  to  recent  reviews,  response  rates  to  these  approaches  are  
75%-88%  and  75%-80%,  respectively15,17.  Blood  and  platelet  
infusions  are  often  necessary  before   instituting  specific  treatment;  
before  administration,  blood  products   should  be  irradiated  to  avoid  
sensitization. 
4. Anaemia  Secondary  to  Treatment  of  Hepatitis 
Currently,  optimal  treatment  for  chronic  infection  with  HCV  
infection  is  a  combination  of  therapy  with  pegylated  interferon  and  
ribavirin.  Of  haematological  abnormalities  that  may  be  associated  
with  such  combination  therapy,  the  most  common  is  anemia20.  
Significant  anemia  (haemoglobin  < 10 g/dL)  has  been  observed  in  
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9%-13%  of  patients  receiving  interferon  and  ribavirin;  moderate  
anemia  (hemoglobin  < 11 g/dL)  occurs  in  about  30%  of  patients  
undergoing  such  treatment19,20,21.   
There  are  several  mechanisms  by  which  anemia  may  occur  
during  combination  therapy  for  HCV  infection,  and  ribavirin  and/or  
interferons  may  contribute  to  anemia.  In  this  context,  hemoglobin  
concentrations  decrease  mainly  as  a  result  of  ribavirin-induced  
hemolysis19.   
Anemia  due  to   ribavirin  leads  to  modifications  of  the  dose  in  
up  to  25%  of  patients,  and  this  type  of  anemia  may  be  problematic  
in  patients  with  HCV  infection,  especially  those  who  also  have  
renal  or  cardiovascular  disorders.  Adherence  to  ribavirin  therapy  is  
one   factor  that  is  critically  important  in  the  treatment  of  HCV  
infection.  Although  ribavirin-associated  anemia  can  be  reversed  by  
reducing  the  dose  of  ribavirin  or  by  discontinuing  the  drug  
altogether,  this  approach  compromises  outcomes  by  significantly  
decreasing   rates  of  sustained  virological  response.   
A  recent  study  reviewed  the  predictors  of  anemia  in  patients  
undergoing  treatment  for  HCV  infection20.  Patients  with  impaired  
renal  function  may  be  at  an  increased  risk  of  ribavirin-related  
anemia  and,  accordingly,  should  be  monitored  carefully.  
Furthermore,  a  decrease  in  haemoglobin  concentration  of  ≥ 1.5 g/dL  
by  week  2  of  treatment  has  been  found  to  be  an  excellent  early  
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predictor  of  subsequent  substantial  decreases  in  hemoglobin.  This  
predictor  might  be  applied  to  identify  candidates  for  early  
intervention  for  management  of  anemia  to  facilitate  maintenance  of  
the  dose  of  ribavirin.  One  of  the  specific  approaches  to  manage  
ribavirin  associated  anemia  is  administration  of  recombinant  human  
erythropoietin20.  After  16 wk  of  ribavirin  therapy,  patients  who  had  
also  been  given  erythropoietin  alfa  had  significantly  higher  mean  
hemoglobin  levels  than  patients  in  a   control  group.  In  patients  with  
chronic  hepatitis  C,  viramidine ,  a   prodrug  of  ribavirin  that  is  
selectively  taken  up  by  the  liver,  has   the  potential  of  maintaining  
the  antiviral  efficacy  of  ribavirin,  while  decreasing  the  risk  of  
haemolytic  anemia22.   
Interferons  may  also  contribute  to  anemia.  Their  main  relevant  
action  is  induction  of  bone  marrow  suppression.  This  effect  of  
interferon  results  in  suppression  of  compensatory  reticulocytosis  
associated  with  ribavirin induced  haemolytic  anemia.  Thus,  the  bone-
marrow  suppressive  effect  of  interferon  may  contribute  to  anemia,  
which  complicates  therapy  with  combination  of  interferon  and  
ribavirin22.   
5. Alcohol, Liver Disease and Anaemia 
Alcohol  is  implicated  in  the  pathogenesis  of  chronic  liver  
disease;  it  may  contribute  to  anemia  secondary  to  its  direct  effects  
on  the   liver  and  also  to  other  diverse  mechanisms  (Figure 1)23. 
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Figure 1 – Depicts how different attributes of alcohol contribute to 
anaemia ( Moreno Otero et al23 ) 
 
Markers  of  iron  overload  tend  to  be  higher  among  those  who  
consume  more  than  two  alcoholic  drinks  per  day  than  among  non-
drinkers,  after  adjusting  for  potential  confounding  factors24.  
Consumption  of  alcohol  appears  to  be  associated  with  an  
approximately  40%   reduction  in  the  risk  of  development  of  iron  
deficiency  anemia.  Folic  acid  and  vitamin  B12  deficiencies  develop  
frequently  in  patients  with  cirrhosis.  These  deficiencies  may  be  
related  to  inadequate  food  intake  or  intestinal  malabsorption.  They  
are  suspected  when  examination  of  a  blood  film  reveals  
hypersegmented  cells  and  oval  macrocytes,  in  addition  to  round  
macrocytes  characteristic  of  chronic  liver  disease.  When  anemia  is  
caused  by  these  deficiencies,  the  mean  corpuscular  volume  is  
increased  and  bone  marrow  shows  megaloblastic  erythropoiesis.   
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Anemia  due  to   folic  acid  deficiency  may  result,  not  only  
from  a  lack  of  folic  acid   in  the  diet,  but  also  the  weak  antifolate  
action  of  ethanol.  Folic   acid  deficiency  is  the  most  common  cause  
of  a  low  hematocrit  in   hospitalized  patients  who  are   alcoholics25,26.   
Parenterally   administered  vitamin  B12  not  only  corrects  
anemia  caused  by  vitamin  B12  deficiency,  but  may  also  induce  
improvement  in  the  peripheral  neuropathy  that  are  associated  with  
this  deficiency23.   Supplements  of  vitamins  A,  B  and  C  may  be  
administered  empirically  to  patients  with  advanced  alcoholic  disease.   
Anemia  in  an  alcoholic  may  also  arise  as  a  consequence  of  
the  direct  toxic  effects  of  alcohol  on  erythrocyte  precursors  in  the  
bone  marrow.  Management  of  alcohol  induced  suppression  of  
erythropoiesis  includes  abstinence  from  alcohol  and  a  nutritious  diet  
with  appropriate  supplements.  Other  factors  that  may  contribute  to   
anemia  and  a  low  hematocrit  in  alcoholic  patients  are  given  in  
Table  3.  
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Table 3 - Etiological factors that may contribute to anaemia 
associated with alcoholism ( Lewis et al26) 
 
 
 
 
 
 
 
 
 
 
6. Anaemia  Secondary  to  Nutritional deficiencies 
 i) Iron  Metabolism   
 Serum iron is bound to Beta globulin transferrin which is 
synthesized in liver.  Total iron binding capacity largely depends on the 
transferrin  concentration27. High total iron binding capacity indicates 
iron deficiency. Iron binding capacity is often lowered in patients with 
liver disease due to decreased synthesis of transferrin. Serum transferrin 
receptor level is a more reliable lab index of iron deficiency in patients 
with liver disease. 
 Iron deficiency is also associated with hemorrhage and hemolysis.  
Iron deficiency causes microcytic hypochromic anaemia. Low or normal 
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serum iron concentration with a low or normal total iron binding capacity 
is frequently found in uncomplicated cirrhosis.  In alcohol induced liver 
diseases, alcohol has a toxic effect and suppresses the bone marrow28,29  
but it increases  the iron  absorption from the GIT. Hepatic inflammation 
and necrosis tend to increase serum ferritin.  The rise in MCV which 
accompanies alcohol ingestion masks the iron deficiency. 
ii) Vitamin  B12  and  Folic  acid  metabolism   
 Intrinsic factor is required for B12 absorption and there is 
significant enterohepatic circulation. Pernicious anaemia is associated 
with primary biliary  cirrhosis30,31.  Alcohol inhibits  B12 absorption,  
elevated B12 binding capacity occurs in cirrhosis and hepatocellular 
carcinoma. Liver stores 5 -10 mg of vitamin B12 representing 50 – 90 % 
of body stores32. 
  Liver stores of folic acid are sufficient for only 4 to 5 months32,33. 
Alcohol induced liver disease and poor nutrition results in disordered 
folate metabolism. Hepatic  necrosis  leads  to increased  release  of folate  
from liver  and leads  to increased  urinary  excretion.  Altered  B12 and  
folate metabolism causes  macrocytosis.  
7. Anaemia  secondary  to  hemolytic syndromes in liver  disease  
 Red  cell life  span in reduced  by about 50 % in cirrhotics  with, 
the spleen  as the major  site of  destruction.  The  hemolysis may be due 
to 
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1. Hypersplenism 
2. Lipid abnormalities.  
3. Hemolytic anaemia is also seen in Wilson’s disease and in 
autoimmune hepatitis (Coombs positive)33.  
4. Intracorpuscular defects such as instability of pyruvate kinase 
enzyme in alcoholic liver disease leads to hemolysis. 
Recticulocytosis is frequently seen in liver disease patients  with  
hemolysis.   
ABNORMALITIES OF RED CELL SHAPE  
Microcytosis is due to Iron deficiency of various mechanisms in 
decompensated liver disease34.  
Macrocytosis is seen mostly in alcoholics 35,36. The increase in 
MCV is due to  
- Increase in RBC membrane cholesterol and phospholipid content.  
- Recticulocytosis associated with hemorrhage and hemolysis.  
- Abnormalities in B12 and Folic acid metabolism.  
- Intrinsic abnormality in bone marrow erythropoiesis.  
Target cells: bowel or saucer shaped thin macrocytes.It is seen in   
seen in most cases of hepato cellular failure   and cholestatic jaundice. 
Raised bile acids inhibit LCAT. So the red cell membrane LCAT is 
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decreased resulting in loading of membrane with cholesterol and lecithin 
forms target cells 37  
Acanthocytosis: Seen in severe liver disease. It is a bad prognostic 
indicator.  Where it is associated with hemolytic anaemia it is called as 
spur cell anaemia38.  
Echinocytes: Speculated red cells due to changes in HDL in Liver 
disease patients.  
Table: 4 Abnormality of RBCs39 
Abnormality Primary  liver disorders Disease  in other  systems 
Macrocytes  Many types of liver  
diseases  
Megaloblastic anaemia, 
Hypothyroidism, cytotoxic drugs.  
Targets cells  Many types  of liver  
disease 
Thalassaemia, Other 
haemoglobinopathies, 
Hyposplenism,  e.g. SLE,  celiac 
disease  
Spherocytes  Zieve's  syndrome  Hereditary  spherocytosis, 
Autoimmune haemolytic  anaemia, 
Burns 
Echinocytes  
Acanthocytes  
Severe chronic liver disease  
Very severe  disease 
(especially  alcoholic) 
(spur-cell anaemia)  
Haemolytic  anaemia   
Abetalipoproteinemia 
Anorexia nervosa / Malnutrition  
McLeod  phenotype 
Burr  cells 
Fragmented 
cells 
(schistocytes) 
Hepatorenal  syndrome  Renal failure, Thoromobotic  
thromobocytopenic purpura, 
Microangiopathic  haemolytic 
anaemia, DIC,  HELLP  syndrome, 
some  haemoglobinopathies  
Stomatocytes, 
Tear – drop, 
poikilocytes  
Alcoholic  cirrhosis  Alcoholism, Haemolytic anaemias 
Primary and secondary 
myelofibrosis  
Nucleated  red 
cells,  punctuate  
basophilla  
Acute fatty  liver of  
pregnancy  
Infections,  e.g.malaria 
Heavy metal poisoning  
Haemolytic / dyserythropoietic 
anaemia.  
Rouleaux, 
Auto 
agglutination  
Sickle cells  
 Myeloma / macroglobulinemia / 
lymphoma / Autoimmune 
haemolytic anaemia  
Sickle cell disease.  
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WBC CHANGES IN LIVER DISEASE  
 Leukocytosis can occur in response to associated infection, 
hemorrhage, hemolysis and malignancy.  Eosinophilia in frequently seen 
in association   with parasitic disease, hepatocellular carcinoma, hepatic 
vein thrombosis, drug induced and also in primary biliary cirrhosis.  
 Leucopenia seen in Liver disease patients is due to hypersplenism40  
or a toxic effect on bone marrow (alcohol). Neutrophil function is 
affected by disturbance in late maturation of granulocyte differentiation. 
Chemotaxis is inhibited. There is a low level of complement C3. 
 Hypergamma globulinemia is a well recognized feature of 
cirrhosis. It is initiated by immunization with enteric organisms normally 
filtered by liver.  IgG and IgA are markedly increased41.  There is 
generalized immunological hyperactivity. Benign  monoclonal  
gammopathy is associated  with primary  biliary  cirrhosis.  
 Specific Immunoglobulins are      
 IgA – Alcoholic cirrhosis  
 IgM – Primary biliary cirrhosis  
 IgG – Auto Immune Hepatitis.  
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DISORDERS  OF  BLEEDING   
PLATELET  AND  CLOTTING  FACTORS  IN  LIVER   DISEASE 
The  liver  plays  a  central  role  in  blood  coagulation.  Acute  and   
chronic  hepatocellular  diseases  are  usually  associated  with  defective   
blood  coagulation  due  to  a  variety  of  different  causes.  These  
include:  decreased  hepatic  synthesis  of  factors II, VII, IX and X;  the   
presence  of  inhibitors  of  these  factors;  decreased  clearance  of   
activated  coagulation  factors;  thrombocytopenia;  impaired  platelet  
function;  hyperfibrinolysis;  and  disseminated  intravascular  
coagulation42,43. 
The  Clotting  Factors : 
 Liver is the principal site of synthesis of all the coagulation protein 
with the exception of vWF and factor VIII C44. The proteins include -  i) 
Vitamin K dependent factors – II, VII, IX & X 
        ii) Labile factor – V 
        iii) Contact factor XI & VII  
        iv) Fibrinogen and fibrin stabilizing factors. 
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A  summary  of  the  coagulation  cascade  is  shown in figure 2 :  
 
Figure 2 – Coagulation cascade. 
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 Liver is the site of vitamin K storage.  The Vitamin K is essential 
for the synthesis of factors II, VII, IX and X. The function  of these  
blood  clotting  proteins depend  on the conversion  of glutamic  acid 
residues, post ribosomally  to γ  carboxy glutamic  acid by a carboxylase  
that requires  vitamin K.  
Factor VII is usually first to be decreased due to its short half life. 
The non functional precursor forms of clotting factors are called proteins 
induced in vitamin K. absence (PIVKA).They are produced with  
defective carboxylation in the presence of vitamin K deficiency. 
Factor V is synthesized in liver in the absence of vitamin K. Thus a 
decreased level of factor V associated with decreased levels of factor II, 
VII, IX and X is an indicator of hepatocellular insufficiency. 
Hypofibrinogenemia is less frequent, until there is severe liver damage. 
Factors XI, XII and high molecular weight kininogen are usually 
moderately decreased. Prekallikrein decreases early in  liver disease. 
Factor XIII, a fibrin stabilizing factor is also decreased. 
An  important  coagulation  defect  associated  with  chronic  liver  
disease  is  low  levels  of  factor  VIIa.  In  recent  years,  the  hemostatic   
agent  recombinant  factor  VIIa  has  become  available  as  a  potentially  
new  therapeutic  agent  for  use  in  the  management  of  coagulopathy   
in  patients  with  cirrhosis.  This  agent  may  enhance  initial  control  of  
acute  variceal  bleeding45.  However,  such  therapy  is  associated   with  
significant  side  effects,  such  as  vascular  injury  and  thrombosis.  
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Functional   abnormalities   of   fibrinogen   molecule   are   known   
as dysfibrinogenemias. Acquired dysfibrinogenemias are most often 
associated with Decompensated Liver disease. Defective polymerization 
results from an abnormal glycosylation of fibrinogen molecules46. An 
increased level of sialyl transferase has been demonstrated in liver 
patients with dysfibrinogenemias47. Impairment in fibrin formation results 
in prolonged thrombin time. Abnormal type of prothrorombin due to 
defective carboxylation in des-γ  -carboxy prothrorombin which is 
increased in chronic active hepatitis, cirrhosis and hepatocellular 
carcinoma. 
Coagulation  defects  complicating  liver  disease  predispose  to  
an  increased  bleeding  tendency,  which  increases  both  morbidity  and  
mortality42,43,48.  Defective  blood  coagulation   associated  with  
hepatocellular  disease  may  be  monitored  using  global  screening  
tests,  such  as  the  PT  and  the  activated  partial   thromboplastin  time.  
In  mild  hepatocellular  disease,  PT  usually  is  within  the  normal  
range  or  only  modestly  prolonged.  In  more  advanced  hepatocellular  
disease,  prolongation  of  PT  tends  to  reflect  the  severity  of  
hepatocellular  failure.  Vitamin  K  routinely  is  administered  
parenterally  (usually  only  once ) to  patients  with  liver   disease  and  a  
prolonged  PT,  to  exclude  vitamin  K  deficiency  as  a   cause  of  the  
prolonged  PT42. 
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Clotting  Inhibitors : 
 Inhibitors of coagulation cascade are also synthesized by the liver. 
These are – Antithrombin III 
 Protein C & S (Vitamin K dependent)  
 Heparin cofactor II  
Protein C, S , and antithrombin III are decreased in hepatocellular 
insufficiency49. The deficiency is not severe and usually parallels that of 
factor V. The synthesis is only affected by general damage to liver. 
Protein C deficiency parallels the deficiency of other vitamin K 
dependent factors. The level of protein S remains significantly greater 
due to extra hepatic source of protein S. 
Although levels of naturally occurring inhibitors of blood clotting 
are decreased in hepatocellular insufficiency clinical evidence of 
thrombo embolism is rarely noted. This is probably due to the balance 
maintained between these inhibitors and the procoagulant. 
Thrombocytopenia : 
Thrombocytopenia  (platelet  count  < 150 000/L)  is  common  in   
patients  with  chronic  liver  disease;  it  has  been  reported  in  as  many  
as  76%  of  patients  with  cirrhosis22,43.  The  pathogenesis  of  the  
thrombocytopenia  is  complex;  it  includes  splenic  pooling,  and  
increased  destruction  and  impaired  production  of  platelets  (Figure 3).  
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Figure 3 - Development of thrombocytopenia in patients with chronic 
liver disease ( Afdhal et al43 ) 
 
Impaired  production  of  platelets  is  caused,  at  least  in  part,  by  
low   levels  of  thrombopoietin.  Prolonged  bleeding  time,  and  
impaired  aggregation,  reduced  adhesiveness  and  abnormal  
ultrastructure  of   platelets  reflect  abnormal  platelet  function;  these  
abnormalities  have  been  attributed  to  an  intrinsic  platelet  defect.  
Specific treatments  to  attempt  to  reverse  the  effects  of  this  defect  
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are  not  usually  given,  but  platelet  transfusions  or  platelet  
stimulating  agents  have  been  administered  in  some  cases.   
Hyperfibrinolysis : 
Hyperfibrinolysis  is  another  cause  of  impaired  hemostasis  in   
patients  with  liver  disease. In decompensated liver disease patient, 
enhanced fibrinolysis is due to decreased hepatic synthesis of inhibitors 
α 2-antiplasmin and plasminogen activator inhibitor as well as decreased 
clearance of tissue type plasminogen activator. 
In  a  nonrandomized  trial50,   antifibrinolytic  amino  acids  were  
administered  to  patients  with  acute  or  chronic  liver  disease,  who  
had  upper  gastrointestinal  bleeding   and  acquired  defects  of  blood  
coagulation.  However,  administration  of  such  amino  acids  does  not  
have  an  established  place  in  therapy.   
Thrombosis  and  Disseminated  Intravascular  Coagulation (DIC) : 
DIC is due to the consequence of non compensated formation of 
thrombin and leads to the formation of platelet thrombi and fibrin within 
the circulation. Thus it is associated with activation and consumption of 
circulating platelets and consumption of factors V, VIII, VII, II & XIII 
Protein C & S, antithrombin III, plasminogen and α plasmin inhibitor51. 
The release of tissue thromboplastin like material by necrotic liver 
had been the triggering factor for DIC in severe liver failure. Increased 
fibrinopeptide - A levels have been found in patients with cirrhosis and 
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chronic hepatitis. Elevated level of thrombin - anti thrombin complexes 
have been reported in chronic active hepatitis, decompensated liver 
disease, end stage liver disease and fulminant liver failure. 
Thrombotic  events,  although  rare  in  patients  with  cirrhosis,  
may  occur.  They  tend  to  involve  particularly  the  portal  and/or  
mesenteric veins. 
Summarising – Hemostasis in  Liver  Disease : 
 The abnormalities in hemostasis are due to  
i. Impaired synthesis of clotting factors.  
ii. Synthesis of abnormal clotting proteins.  
iii. Quantitative,  qualitative  platelet  defect  
iv. Enhanced  fibrinolytic  activity  
v. Disseminated intravascular coagulation52.  
A rational  approach  to  managing  disorders  of  blood  
coagulation  in  patients  with  liver  disease  is  important  because  of  
the  high  risk  of  associated  secondary  hemorrhage.   
PLASMA  VOLUME  
 Plasma volume is frequently increased in patients with cirrhosis 
especially with ascites. Hypervolemia causes low peripheral hemoglobin 
or erythrocyte  level53.  
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 The  haemotological  abnormalities  discussed  are  summarized  in  
the  following  Table-5  and  Figure-4.  
TABLE-5 
COMBINATION OF HAEMATOLOGICAL ABNORMALITIES 
WITH54 ABNORMAL LIVER FUNCTION TESTS 
 
Abnormality Haematological indices 
Primary liver 
Disease Disease in other systems
Red cell 
anaemia 
Increased MCV 
(macrocytic) 
Many liver diseases Alcoholism, Vitamin 
B12/folate deficiency 
Haemolysis  
 
 
 
 
 
 
 
Low MCV/MCHC 
(microcytic) 
Normochromic 
Normocytic 
High reticulocyte 
count 
Low reticulocyte 
count 
With iron deficiency 
 
With  dilutional 
anaemia 
With hypersplenism 
 
With marrow aplasia 
(viral hepatitis) 
Thalassaemia 
 
Anaemia of chronic 
disease 
Haemolysis Paroxysmal 
nocturnal haemoglobinuria  
 
Normal 
haemoglobin 
Erythrocytosis 
Increased MCV 
Low MCV 
Mild liver disease 
With iron deficiency 
Hepatocellular 
carcinoma 
Viral hepatitis (rare) 
Alcoholism 
Thalassaemia trait 
White cells Increased 
 
Neutrophils 
increased 
 
Lymphocytes 
increased 
Eosinophils 
increased 
With infection. 
neoplasia inflammation
With bacterial 
infection or steroid 
therapy 
Viral infections 
 
Parasitic infection 
Drug hepatitis 
Chronic active 
hepatitis   (rare), 
sarcoidosis 
Myeloproliferative 
disorder 
Leukemia, Lymphoma, 
drugs  
 
Connective tissue 
disorders 
 
 
 
 
Monocytes  
Basophils 
Mast cells 
increased 
 
 
 
 
 
 
Tuberculosis, Leukemia, 
myeloprolifcrative disease 
 
Mastocytosis 
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Abnormality Haematological indices 
Primary liver 
Disease Disease in other systems
 
 
Decreased 
 
With infection, 
marrow aplasia, or 
hyposplcnism 
Infections (typhoid, SBE, 
tuberculosis,  septicaemia)
leukemia 
 Lymphocytes  Viral infections 
Platelets 
 
 
 
 
Increased 
 
Decreased 
 
Hemorrhage 
inflammation 
With hypersplenism. 
viral hepatitis 
 
 
 
Myeloproliferativc 
disorder 
Leukaemia/lymphoma 
Connective   tissue   
disorders 
Paroxysmal              
nocturnal  
haemoglobinuria 
 
HAEMATOLOGICAL ABNORMALITIES IN DECOMPENSATED 
CHRONIC LIVER DISEASE32 
The Haemotological abnormalities in chronic liver disease add 
morbidity to the primary pathology and increase the mortality. The 
possible factors are summarized in Figure 4.  
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Figure - 4 
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DESIGN OF STUDY 
MATERIALS AND METHODS 
To assess the prevalence  of various hematological abnormalities in 
chronic liver disease, the study was conducted in Chengalpattu Medical 
College Hospital during the period from Sept 2010 to Nov 2010.  A total  
50 patients were selected in for this study.  
All the cases included in the study were admitted in the hospital 
ward and were evaluated for chronic liver disease and the hematological 
abnormalities. Oral consent for the clinical examination and for the lab 
investigations were obtained from all patients. Written consent  was 
obtained  for  bone  marrow study.  
All the patients were interrogated regarding their symptoms, like  
duration of illness, bleeding tendencies, abdominal distension, jaundice 
and oliguria and  past history regarding previous treatment of diabetes, 
hypertension, tuberculosis, coronary heart disease, trauma, blood 
transfusion, surgery needle pricks and contact with blood products. 
Personal history regarding alcoholism, smoking, high risk behavior 
and  family history of any liver disease was also noted. Then the patient 
was subjected to general examination and systemic examination  and  
were submitted to blood investigations.  
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Patients were   diagnosed to have  decompensated  chronic  liver  
disease  by   combined  clinical  and  radiological  workup.  Clinical  
parameters  included  signs  of  liver  failure  whereas  radiological  
parameters  included  proven  hepatic  cirrhosis  with  portal  
hypertension  and  splenomegaly  by  ultrasound.  
After    establishing    the    diagnosis    patients    were    evaluated    
for hematological abnormalities. All blood investigations regarding 
hematological profile were done in clinical pathology laboratory in 
Chengalpattu  Medical College Hospital. Bone  Marrow  aspiration was  
done  in  the  medical  wards  under  strict  aseptic  precautions.  
Similarly prothrombin time and activated partial thromboplastin 
time were done at outside laboratory. 
TO ASSESS RBC ABNORMALITY 
1.       RBC count : 
RBC count was done with  Neubauer's chamber using Hayem's 
fluid or auto analyser44.  
Normal Value: 
1. Male 4- 5 to 5.9 x 106 mm3  
2. Female 4 to 5.2 x 106 mm3 
 35
2.        Hemoglobin estimation : 
Done by Sahli's method, based on conversion of hemoglobin to 
acid hematin or acid analyzer. 
 Normal value: 
1. Male 13.5 to 17.5 gm % 
2. Female 12 to 16 gm %  
3.        Packed cell volume (PCV) : 
It was done in autoanalyser or using microhematocrit capillary 
method.  
Normal value:  
1. Male 42 to 52 % 
2. Female 37 to 47 %  
4.       MCV, MCHC, MCH : 
 Were  estimated  by  autoanalyser  
 (I) MCV = 
cummpermillioninRBC
PCVx10  
  80 – 97 FL – Normal 
  < 80- microcytic 
>97 – macrocytic 
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(ii) MCH = )(10 Pg
cummpermillioninRBC
Hbx  
                      27 - 31 -  Normal 
< 27 – Hypo chromic 
> 31 - Hyper chromic 
 (iii) MCHC = (%)100
PCV
Hbx  
  32 – 36  %  - Normal 
  < 32 Hypo chromic 
  > 36 – Hyper chromic  
5.        Peripheral smear for blood picture : 
Using Leishmann's stain blood picture was examined with a lab 
microscope. 
      (i) Low power field examination: 
-    Quality of film 
-   Number, distribution and staining of WBCs 
-    RBCs examination 
(ii) High power field examination: 
              Assess RBC - Size, Shape, Hemoglobin concentration 
(iii) Oil immersion examination: 
              Assess atypical cells and inclusion bodies 
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6.       Reticulocyte count : 
Stain - 1% brilliant cresyl blue 
Normal – 0.2 – 2 % 
7. Bone marrow study (not conducted  in 23  patients  because of  
hemostatic abnormalities55,56.  
II ) To assess WBC abnormality : 
1. Total WBC count 
Done by QBC method or using Neubauer's chamber with Turke's 
fluid. Normal 4,500-11,000 cells per cmm27 
2.  Differential  count  
Assessed by QBC method or direct staining and visualizing with 
lab microscope. 
III) To Assess hemostasis : 
1. Platelet count 
 Manually was done by Rees Eecker method (staining with 
brilliant cresyl blue dye or by auto analyzer).  
 Normal 1.5 to 3.5 x 105 / mm 3 
2. Prothrombin time :  
 Done by Quick one stage method. Normal (10 – 14 sec).  
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3. Bleeding time – By Ivy's method- Normal (1-7 mts) 
4. Clotting time   by lee & white method – Normal (5 -15 min) 
5. Activated partial thromboplastin time Normal (24 – 34 sec). 
IV. Liver function test : 
In fifty cases, the following biochemical investigations were 
carried out to prove the presence and assess the severity of hepatocellular 
failure.  
1. Serum Proteins  Total  Albumin 
  Differential  Globulin  
 
2. Serum billirubin Total   Conjugated 
  Differential   Unconjugated  
3. Serum Alkaline phosphatase 
4. AST and ALT. 
INCLUSION CRITERIA 
1. Adult patients presenting with signs and symptoms of chronic 
liver disease. 
2. Liver  function  tests  showing  indication  of  liver  disease 
3. USG  showing  cirrhotic  liver  with  portal  hypertension  and  
splenomegaly 
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EXCLUSION CRITERIA 
1. Acute liver cell failure, as  characterized  by  normal  liver  
echotexture  by  USG 
2. Patients   with   known    GIT   malignancy   or   known   primary 
hepatocellular carcinoma. 
3. Patients with primary coagulation disorder, 
4. Liver cell failure due to infective cause like septicemia or end 
toxemia. 
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DATA ANALYSIS 
This study regarding assessment of hematological profile and 
hemostasis was conducted among 50 inpatients in medicine department at 
Chengalpattu  Medical College Hospital.  
Age  and  Sex  Distribution : 
Out of 50 patients in this study, there  were  40 male patients and 
10 female patients. The age of patients in this study was in the range from 
20 to 60  years  as  shown  in  Table-6, Figure-5  and  Figure-6. 
Table 6 – Age  Distribution of  the  study  group 
Age Percentage. of Cases No.of Cases Male Female 
20 to 30 6% 3 2 1 
30 to 40 38% 19 15 4 
40 to 50 40% 20 16 4 
50 to 60 16% 8 7 1 
 
 Most of the patients in the study were in the middle age group 
and only 6% were in younger age. Out of 3 patients one patient was 
diagnosed to have Wilson's disease and others were of unknown etiology. 
Remaining 47 patients were diagnosed as chronic decompensated liver 
disease with pathology as cirrhosis and were of variable etiology.  
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Figure -5  
 
Figure - 6 
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PRESENTING  HISTORY   
ALCOHOLISM 
Among 10 female patients, none gave history of alcoholism and 
among the 40 male patients 36 patients were found to be alcoholics. 
HISTORY OF JAUNDICE  
Among 50 patients only 25  patients had  history of jaundice. Later 
serologic   investigations for HBV Ag. Anti HCV antibody showed 6 
patients positive for HBS Ag and only one shows positive for anti HCV 
antibody. 
While coming to data analysis of investigations, among the 50 
Chronic Liver Disease patient’s only 43 patients has raised billirubin 
level. About 7% of the patients were with normal billirubin level. 
TABLE – 7 -  ANALYSIS OF SYMPTOMS 
Symptoms No.of Cases Percentage of Cases 
Weakness  & Fatigue 37 74% 
Anorexia  34 68% 
Nausea / Vomiting 22 44% 
Distention of  abdomen 50 100% 
Jaundice 25 50% 
Bleeding Tendency 24 48% 
 
 43
 Among the 50 patients 68 % had anorexia and  74 % had  
weakness  and fatiguability. Jaundice was found in 50 %. Bleeding 
tendency was observed in 48 % of them.  
 
Figure 7 – Common Clinical Symptoms 
CLINICAL  EXAMINATION 
 Among the 50 patients, 50% had Jaundice and 54% had anemia. 
Splenomegaly was  observed in 92%. Ascites  was  present  in  100% of  
the  patients. 
 Table – 8  and  Figure – 8  summarises  the  clinical  findings  in  
the  study  group. 
 
 
 
 
 44
TABLE – 8  -  ANALYSIS OF SIGNS: 
No. SIGNS No. of cases % 
1 Anaemia  27 54% 
2 Jaundice  25 50% 
3 Pedal edema 33 66% 
4 Spider  angiomas  3 6% 
5 Purpura & Bruises  3 6% 
6 Gynaecomastia and Testicular atrophy 10 20% 
7 Dilated veins over abdomen 18 36% 
8 Splenomegaly 46 92% 
9 Ascites  50 100% 
10 Asterixis 4 8% 
 
 
Figure – 8 – Analysis  of  Signs 
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Fig. 9  Jaundice 
ANALYSIS OF RBCS 
Patients in the study were analysed for the presence and absence of 
anaemia and the characteristics of anaemia when present.   
 44 patients had anaemia and only six patients had normal 
hemoglobin above 12 gm%.  About 14  patients had severe anaemia less 
than 8 gm%. 
Table -9 - Anaemia in Chronic Liver Disease 
Haemoglobin gm % Cases Percentage 
< 6 2 4% 
6 to 8 12 24% 
8.1 to 10 22 44% 
10.1 to 12 8 16% 
12.1 to 14 6 12% 
> 14 Nil    
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Table 10 -  RBC count in chronic liver disease 
RBC Count Cases Percentage 
2.5 to 3 8 16% 
3 to 3.5 10 20% 
3.5 to 4 17 34% 
4 to 4.5 11 22% 
> 4.5 4 8% 
 
 
Figure - 10 
 
 
Figure - 11 
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CHARACTERISTICS OF ANAEMIA 
All the 6 patients with normal hemoglobin level had 
normochromic and normocytic blood picture.  Among the 44  patients  
with  anaemia, 11  patients had normochromic and normocytic anaemia, 
11 patients had microcytic anaemia and 11 patients had macrocytosis. 
Only one had dimorphic anaemia.  Patients with microcytic anaemia 
showed anisocytosis  and  poikilocytosis.  
Target cells were seen in only six patients. Acanthocytes was not 
seen in any of the peripheral smears. Patients with macrocytosis had 
meant  corpuscular  volume  more  than  97 fl.  
Table 11 -  Type of Anaemia 
Type of RBCs Patients with anaemia Percentage 
Normocytic  11 22 % 
Microcytic  11 22 % 
Macrocytic  11 22 % 
Dimorphic 1 2 % 
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TYPE OF ANAEMIA 
BLOOD PICTURE 
 
Microcytic Hypochromic Anaemia With Tear Drop Cell 
 
 
Macrocytosis with Hypersegmented Neutrophils 
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BLOOD PICTURE 
 
Target Cells 
 
Acanthocytes 
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WBC ABNORMALITIES  
 The analysis of WBCs was done with the total count and the 
differential count. The total count of WBCs range from 2700 / mm3 to 
17,000/mm3.  
Among the 50 patients Leukocytosis were observed in 11 patients.  
Eosinophilia was found in two patients.  Leukocytosis  were observed  in 
patients  with fever  due to secondary infection of ascites due to repeated 
paracentesis  and four  patients  had Leukocytosis  due to  spontaneous 
bacterial peritonitis. Leucopenia   was present in 12% of patients.  
Lymphocytosis seen in 12 % of patients, Eosinophilia in 4 % of patients.  
Table 12 -  WBC COUNT IN CHRONIC LIVER DISEASE 
Total  count in Cells / mm3 No. of patients Percentage 
< 3000 3 6% 
3000 – 6000 8 16% 
6000 – 9000 12 24% 
9000 – 12000 16 32% 
> 12, 000 11 22% 
 
 
 
Figure 12 -  WBC Count in Chronic Liver Disease 
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PLATELET  ABNORMALITIES 
Table 13 -  Platelet Count in Chronic Liver Disease 
Total  count in Cells / mm3 No. of patients Percentage 
< 50,000  4 8% 
50,000 – 1,00,000 6 12% 
1 – 1.5 Lakhs  13 26% 
1.5 – 2 lakhs 14 28% 
>  2 lakhs 13 26% 
 
 
Figure 13 – Platelet Count  in DCLD 
Thrombocytopenia was found in 23 patients among 50 cases is the 
study. Severe thrombocytopenia  of < 50,000 cell / mm3 was found in 
patients  with large  spleen >8 cms  and had a history  of massive 
hemetemesis.  Thrombocytopenia  was associated  with history of atleast  
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an episode of hematemesis. Among the patients with severe 
thrombocytopenia 3 patients were found to have disseminated 
intravascular coagulation, later confirmed by the raised value of APTT 
and PT.  
Among the patients with normal level of platelets about 6 patients 
had history of atleast on episode of hematemesis.  Among  the 27 patients 
with normal  platelet  levels about  11 patients  had mild  Splenomegaly  
and 6 patients had moderate  splenomegaly. In 5 patients Splenomegaly 
was observed in Ultra Sonogram only.  
SERUM PROTEINS 
Patients were analysed for the estimation of serum proteins, which 
is the synthetic function of the liver and evaluated for albumin globulin 
ratio which will be altered in the chronic liver disease patients. 
Table 14 - Serum Proteins in Chronic Liver Disease 
Total proteins gm% No of patients Percentage 
>6 7 14% 
6 to 5 22 44% 
5 to 4 17 34% 
<4 4 8% 
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Among patients only 14% had total proteins more than 6 gm% and  
four patients  had total protein <4 gm% and others  were in the middle 
group. 44% had protein in the range of 6-5 gm% and 34% had protein in 
the range of 5-4 gm% .  
All the patients had albumin globulin ratio reversal, which  again, 
favours the diagnosis of Chronic Liver Disease. 
 
 
Figure - 14 
ABNORMALITIES IN COAGULATION  
The liver secretes all the clotting factors,  except factor  VIII and 
VWF.  As  we had no facility  for the  estimation of individual  clotting  
factors,  the patients were  assessed  for the coagulation  profile by testing  
for prothrombin  time and  activated  partial thromboplastin time.  Among 
the 50 patients 20 patients had prolonged prothrombin time and 30 
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patients had normal prothrombin time.  There was no correlation between 
the severity of jaundice and the prolongation of prothrombin time.  
Among the 20 patients with prolonged prothrombin time about 8 
patients had history of atleast one episode of hemetemesis.   
Table 12 - Hemostatic Parameters 
No Type of  change No. of cases % 
1. Platelet Count     
 Normal (>1.5 lakhs) 27 54 % 
 Low normal  (1-1.5 lakhs) 13 26 % 
 low (< 1 lakhs) 10 20 % 
2. Bleeding time   35 70 % 
 (1-7 mts) Normal  35 70 % 
  Prolonged  15 30 % 
3 Clotting time     
 (<15 mts) Normal  50 100 % 
  Prolonged 0 0.0 
4 Prothrombin time    
 (10-14 sec.)  Normal  30 60 % 
  Prolonged 20 40 % 
5. APTT (24-34 sec) Normal  48 96 % 
  Prolonged  2 4 % 
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Bleeding time was prolonged in the 10 patients  who had  platelet  
counts  less than 1,00,000 / mm3 Bone marrow study  was not done  with 
the patients  with low platelet  count and prolonged prothrombin time due 
to the risk  of increased bleeding. 
Among the 50 patients, APTT was prolonged in 2 patients. It was 
significantly raised in patients with DIC.  They had history of 
spontaneous  bleeding  with internal bleeding and signs of endotoxemia.  
Both the two had severe  thrombocytopenia with platelets < 50,000 / mm3 
Bone marrow biopsy was done in all patients  except those patients 
who had abnormal coagulation profile. Most of patients had 
normocellular bone  marrow and 22% patients had hyper cellularity. 
There was no hypoplasia and aplastic changes.  
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DISCUSSION 
The study involving 50 patients done at Chengalpattu Medical 
College Hospital has thrown light over the hematological abnormalities 
of  decompensated chronic liver disease. The results of this study 
confirms with previous published reports.  
RBC ABNORMALITIES  
In the study we inferred that 88 % of the total patients had anemia 
and among them 14 % of cases had Hb < 8 gm %. 
According to studies by McHutchison JG, Manns MP, Longo DL;  
definition and management  of  anemia  in  patients  infected  with  
hepatitis  C   virus in  Liver  Int  2006; 26: 389-398; Anaemia  occurs  in  
75 % of  patients with  chronic  liver  disease.  
Similar  studies  conducted by Kimber C, Deller DJ and Lander 
H57; The mechanism of anemia in Chronic Liver Disease, in 1965; and by 
Sheehy W and Berman A; Anaemia occurs in upto 75 % of patients with 
chronic liver disease. It is characteristically of moderate severity and is 
either normochromic normocytic or moderately macrocytic.         
In our study 14 % patient had severe anemia less than eight gm per 
cent. In patients with cirrhosis , anaemia is  mostly due to. 
I. Portal  Hypertension  and  variceal  bleed 
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II. Hypersplenism  secondary to splenomegaly  in portal  
hypertension 
III. Defective  coagulation 
IV. Effects of  alcohol  on  bone marrow 
V. Aplastic anaemia 
VI. Treatment  induced anaemia 
VII. Decreased  erythropoietin level as per  the study  Siciliano 
Hepatol 1995 who showed  decreased  erythropoietin  level 
in cirrhosis  patients  with anemia when compared  with 
patients  with hypochromic anemia  due to iron deficiency.  
VIII. Chronic inflammation in cirrhosis suppresses the bone 
marrow.  
Anaemia state is further worsened by accompanying   
1. Bleeding esophageal and anorectic varies.  
2. Bleeding peptic ulcer and gastropathy 
3. Malignancy 
4. Bleeding  diathesis 
In developing countries like India, people with poor socio 
economic state already will have nutritional anemia due to iron deficiency 
and B12 and folic acid deficiency, which is superimposed with cirrhosis 
leading   to severe anemia.  Female patients had a greater proportion of 
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severe anemia when compared with males. It shows the poor nutritional 
status of women in developing countries.  
SERUM PROTEINS  
As per Tavill AS study, fall in protein concentration usually reflect 
decreased hepatic synthesis58.  In our study 100 % of cases had decreased 
albumin and total protein level and 90 % patients had albumin-globulin 
ratio reversal. The hypoproteinemia  was also contributed  by poor socio 
economic  status  of the patients  who got admitted at  the government  
hospitals.  
The mechanism for the low albumin level in cirrhosis is due to 
decreased synthetic function of liver. In cirrhosis there  is a chronic  
inflammatory7 process in progression  which causes elevated  cytokines  
level such as IL-1, IL-6 and TNF-α which  inhibits the synthesis of 
albumin and transferrin . About 10 gm of albumin is synthesized by 
normal liver, where as with cirrhosis, it synthesis only about 4 gms.  
CHARACTERISTICS OF ANAEMIA  
According to James Dooley, most common anemia seen in 
cirrhotic patients is normochromic and normocytic  anemia32. 
In our study, interestingly, the prevalence of  normocytic, 
normochromic  anaemia was equal to that of microcytic  and macrocytic 
anaemia. The incidence of normochromic normocytic anemia in our 
patients is 22 %. Where as in some studies there are varied results.  
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According to study done by Malhotra59, 1951, the incidence of 
normocytic, normochromic anaemia was 90 %. In studies done by Bhatia 
(1961) and Mishra ET. al., (1982), the incidence were 59 % and 79 % 
respectively.  
In some studies such as Kimber C. ET. al., reported 43 % of 
macrocytosis, which was supported also by the study by Bingham et al. 
MACROCYTOSIS 
The incidence of macrocytosis in our patients was 22%. 
Macrocytosis in cirrhosis is mostly due to the toxic effect of alcohol on 
RBC production in the bone marrow and deficiency of B12 and folic 
acid60. Folic acid deficiency is also exacerbated with alcohol61 which was 
confirmed by the study done by Weir, Biochem, Pham 1985, and 
Lindenbaum62. 
MICROCYTOSIS  
About 22% patients in our group had microcytic hypo chromic 
anemia. Bleeding,  from esophagus and  peptic  ulceration or esophageal 
varies, compounded by the haemostatic defects of chronic liver disease, 
occurs in upto 70% of patients with Liver disease as per the study 
conducted by Kimber, Philips, et al. Microcytosis in cirrhosis is  due to :    
i. Decreased total iron concentration with alterations in iron 
metabolism due to decreased to serum transferrin.  
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ii. Hemolytic due to hypersplenism, autoimmune process, Lipid 
abnormalities or intra corpuscular defects. 
The Total Iron binding capacity (TIBC) is often lowered in 
cirrhosis due to reduced hepatic synthesis of transferrin. 
ABNORMALITIES OF WBCs 
In our study group all the 50 patients WBC total count are in the 
range of 2700-17,000 cells  per mm3. About 11 patients  had 
Leukocytosis  which  was mostly  due to infections  due to community  
acquired  infections,  nosocomial infection, spontaneous  bacterial 
peritonitis  and secondary peritonitis due to repeated peritoneal 
paracentesis.  
In our study group in patients with Leukocytosis >12,000 / mm3 of 
blood most of the patients had history of repeated hospital admissions 
and had repeated paracentesis. About 50 % of patients with Leukocytosis 
and high grade fever and all patients with Leukocytosis had increased cell 
count mostly of polymorphs in ascetic fluid analysis, which suggests the 
presence of peritonitis in this group of patients. Spontaneous bacterial 
peritonitis is one of the important causes of Leucocytosis27.  
Leucopenia present in 12 % of the patients may be due to  
i. Direct influences of alcohol on bone marrow.  
ii. Chronic inflammatory cytokines having suppressor effect on 
bone marrow.  
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iii. Hypersplenism 
iv. Infection.  
Eosinophilia is seen in association with parasitic disease and also 
associated with Hepatic vein thrombosis, hepatocellular carcinoma, and 
drug allergy and graft rejection.  It is also found in primary biliary 
cirrhosis. Serum  eosinophilia cationic protein is high in patients with 
primary biliary cirrhosis. Eosinophilia is present in 2% of cases in our 
study group mostly due to parasitic infection.  
IMMUNOGLOBULINS AND LIVER DISEASE 
As per the studies  by Feizi Gut (1968) and Jensen, Arch Int Med., 
198263 ,  it has  been proved  that  hyperglobulinemia is a well recognized 
feature of cirrhosis. It has been suggested that this polyclonal  
hypergamaglobulinemia is initiated  by immunization with enteric 
organisms normally filtered by the Liver.  
Cirrhosis may be associated with a  state of generalized immune  
hyperactivity, perhaps as a result of a defect  of immune  regulation.  
Peripheral blood mononuclear cells from cirrhosis with 
hypergamaglobulinemia had a normal proportion of B cells but that IgG 
and IgA hypergamaglobulinemia synthesis was markedly increased.  
In our study almost all patients had hypergamaglobulinemia and  
90 % of  patients  had albumin-globulin ratio reversal.  The ratio reversal 
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is also contributed by lower albumin concentration due to decreased 
synthesis.  
PLATELETS ABNORMALITIES  
Defects of platelet number and function are well documented   in 
patients with chronic liver disease contributing significantly to their 
hemostatic abnormalities. Alcoholic  liver  disease  is associated with 
additional  abnormalities which  are probably  a consequence  of the toxic 
effect  of alcohol  on platelet  production  and function  as proved by the 
studies by Mikhandes BMJ, 1986, Hilbom BMJ 198764.                  
Causes for thrombocytopenia are : 
i. Shortened life span 
ii. Platelet pooling in an enlarged spleen65 
iii. Inability of bone marrow to compensate 
iv. Reduced thrombopoietin level 
 In our study the above findings are evident and out of 50 patients 
10  patients had thrombocytopenia < 1,00,000 / mm3 and 13 patients had  
mild thrombocytopenia( 1 – 1.5 lakhs / mm3). All the patients with count 
less than one lakh  had history of  bleeding tendencies and among them 
two patients were diagnosed to have DIC, which also contributed to the 
very low platelet count in cirrhosis. All the patients with platelet count 
less than one lakh  had increased bleeding time.  
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ABNORMALITIES IN HEMOSTASIS 
 Liver plays a major role in regulating hemostasis, synthesizing 
most of the clotting factors and coagulation inhibitors66, 67, as well as 
some proteins of the fibrinolytic activated enzymes of the clotting and of 
the fibrinolytic system68, 69. 
 The contributing factors are   
1. Defective synthesis of coagulation factors 
2. Thrombocytopenia  
3. Increased fibrinolytic activity  
4. Intravascular coagulation. 
As per the studies Manner Ej, 1992 and Colman RW and Rubies 
R.N. blood coagulation 198870, clotting factors may be decreased even 
before any other evidence of liver damage71, 72. In hepatic cellular failure, 
factor VII is earliest to be decreased due to its short half life then 
followed by factors II and X. Factor IX is usually the last to be affected. 
 These  vitamin  K dependent clotting factors are  synthesized in 
Liver. If their  deficiencies are unresponsive to parenteral administration 
of vitamin K, it can be assumed that the hepatic synthesis of clotting 
factors is impaired. 
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PROTHROMBIN TIME ABNORMALITIES 
 In our study 20  patients had elevated prothrombin value which is 
evidence of clotting factor deficiency. They were treated with vitamin K 
injection for a period of one week and the prothrombin time was 
repeated. Some showed decrease in the prothrombin value  
APTT ABNORMAILITY    
 APTT is prolonged in all coagulation defects including platelet 
activity and thromoboplastin. Prolonged APTT can be due to:  
1. Vitamin K deficiency  
2. Liver disease46 
3. Presence of circulating anticoagulants.  
4. Disseminated Intra vascular coagulation  
In our study two patients had DIC and they had significant 
prolongation in APTT along with increased PT with severe 
thrombocytopenia.  Other patients with history of bleeding tendencies 
were found to have moderately increased APTT.     
According to James Dooley, APTT may be found to be moderate 
to highly prolonged according to the degree of liver  failure32. In case of 
moderate  deficiencies  of factor II, IX, X  and V, associated  with a high  
level of factor  VIII,  APTT can be normal.73 
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DISSEMINATED INTRAVASCULAR COAGULATION  
In our study 2 patients were found to have DIC and it was 
confirmed with prologation of PT and APTT along with severe 
thrombocytopenia and was confirmed by estimation of D-dimer. These 
patients were found to have septicemia, and they had blood  culture 
positivity for gram negative organisms.  
SUMMARY 
Thus with the above studies we  can infer that many of the 
haematological abnormalities  noticed in  decompensated  chronic liver 
disease patients, contribute  to  the  co-morbidity, which may in turn, 
reduce  overall   mortality.  
From the above study we noted that the presence of severe anemia 
does not correlate with severity of disease as evident by normal serum 
billirubin and hypoalbuminemia. Instead it is related with history of 
bleeding tendency.  
The character of anemia depends upon the various factors such as 
bleeding tendencies, dietary deficiency and  alcoholism, but 
normochromic normocytic anemia is more common as  per  literature,  
and is  mostly due to the  hemodilution, blood loss and chronic 
inflammation suppressing the bone marrow. The Leukocytosis is 
associated with infections,  mostly, secondary peritonitis due to repeated 
paracentesis and spontaneous bacterial peritonitis. 
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Platelet abnormalities as assessed by thrombocytopenia and 
increased bleeding time had no correlation with the severity of liver cell 
failure, but found to be  best associated  with  patients with large spleen 
and  more common in patients with bleeding tendencies. 
Similarly prothrombin time and APTT are prolonged. This is 
correlated with the liver disease and there is significant rise in APTT 
along with severe thrombocytopenia  in patients with DIC.     
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SUMMARY 
50 patients of   decompensated   chronic   liver   disease  
were studied. 
1. Almost 88% of the patients had anemia in any one of the form. 
2. There  was  an  equal  distribution of  normochromic normocytic,  
macrocytic  and  microcytic  anaemia as inferred from the study. 
3. Microcytic anaemia is found in 22%  of studied population   
4. Macrocytosis (22%) is almost common with alcoholics. 
5. Abnormal red cells such as microcytic, microcytic, target cells, 
anisocytosis are found to be common in cirrhosis. 
6. Leucopenia  is  found  in  12 %  of  the  study  group. Leukocytosis 
is more common in patients with spontaneous bacterial peritonitis 
and secondary peritonitis. 
7. Thrombocytopenia is present in  23% of patients and is commonly 
present in the patients with Splenomegaly and with the history of 
bleeding tendencies. 
8. Prothrombin time prolonged in 40% of the patients. A significant 
rise in APTT with severe thrombocytopenia is found is DIC patients. 
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CONCLUSION 
 
1. There  is  an  equal  prevalence  of   normochromic normocytic,  
microcytic  and  macrocytic  anaemia. Microcytosis occur in 
patients with bleeding tendencies and macrocytosis occurs mostly 
in alcoholics. 
2. Leucopenia occurs in a small fraction of patients and Leukocytosis 
occurs in patients with history of repeated paracentesis and 
peritonitis. Eosinophilia is associated with parasitic infections. 
3. Thrombocytopenia is present in most of the cirrhosis patients and is 
associated with increased bleeding tendencies. 
4.  Increased  prothrombin  time  and  APTT  occurs  due  to decreased 
synthesis of clotting factors. 
5. All the cirrhosis patients must be evaluated for hematological and 
haemostatic abnormalities. Early treatment to correct these  
co-morbidities can decrease the  overall  mortality. 
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1 38 M 26172 4.1 9.3 30 74.6 20.4 27.3 6900 P65L33E1M1 Normal 
microcytic  
Hypochromic Normal 4 6 11 23 4.9 2.4 2.5 1.1 0.4 0.7 90 66 41
2 45 M 26265 3.6 8.8 34.0 89.3 29.5 33.0 8400 P63L37E0
Low 
Normal 
Normocytic 
Normochromic Normal study 5'45 5'30 13 21 5.2 2.1 3.1 3.6 2.2 1.4 46 38 79
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microcytic  
Hypochromic
Macronormo 
blast 4 6 11 23 5.6 2.8 2.8 4.8 3 1.8 102 89 86
4 47 M 27200 2.6 5.5 27.0 77 24.0 31.0 14800 P50L46E4 Mod
Microcytic 
Hypochromic Not done 8'3 5 17 23 5.9 3 2.9 3.2 2.6 0.6 69 97 80
5 35 M 27274 2.8 6.7 33 101.0 34.0 34.7 6600 P67L30E3 Normal 
 macrocytosis 
Target cells Not done 4'30 6'45 17 21 5.0 2.1 2.9 4.6 3 1.6 97 102 98
6 39 F 27512 3.4 8.7 33.0 83 24.1 30.0 9300 P62L36E1M1 Mod
Normocytic 
Hypochromic Not done 4 6'15 11 24 4.2 2 2.2 2.6 1.9 0.7 63 43 73
7 59 M 29273 4.3 9.9 33 108.6 30.6 27.8 12500 P65L32E2 Normal 
 macrocytosis 
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Erythroid 
Hyperplasia 6' 15 8 15 22 4.9 2.4 2.5 5.1 3.1 2 78 67 94
8 34 M 29861 3.9 8.9 36.0 73 22.0 30.0 3600 P49L46E4 Normal 
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Normocytic 
Hypochromic Normal 4'30 6 15 21 4.5 2 2.5 5.2 3.2 2 78 89 92
16 42 M 34192 4 11.5 32.0 102 29.6 28.6 3600 P50L46E4 Mod  macrocytosis  Normal 5'30 6 12 25 6 3 3.0 1.4 1 0.4 68 46 79
17 37 M 34747 3.9 11.1 19 105.0 27.8 36.5 2700 P49L45E4M2 Normal 
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18 36 M 35036 3.4 8.0 33.0 120 39.0 33.0 9200 P54L44E2 Mod  macrocytosis  Not done 5 4 13 27 4 1.8 2.2 4.6 3 1.6 92 69 67
19 29 M 35104 4.2 8.9 44 88.6 26.0 28.2 15200 P78L21E1 Normal 
Normocytic 
Hypochromic Normal 7 7'30 15 28 4 1.9 2.1 4.9 3 1.9 79 74 74
20 36 F 35196 2.7 7.3 31.0 104.4 32.3 31.3 2900 P50L46E4 Mod  macrocytosis  Not done 8'15 6 13 23 4.9 2 2.9 1.8 1 0.8 48 46 50
21 35 F 35229 4.0 9.1 38 91.2 30.7 34.0 6050 P48L36E10M6 Normal 
Normocytic 
Normochromic Not done 6'30 5 11 21 3.4 1.7 1.7 3.1 2.3 0.8 69 84 76
22 33 M 36644 3.4 7.7 33.0 79 24.0 30.3 8600 P62L36E2 Mod
Normocytic 
Hypochromic Not done 8'30 6'30 14 28 4.2 1.6 2.6 3.2 2 1.2 61 47 94
23 35 M 36695 4.0 11.9 42 81.3 26.8 33.1 9300 P72L26E2 Normal 
Normocytic 
Normochromic Normal 9'0 5'3 17 27 6.1 3 3.1 2.6 2 0.6 77 71 48
24 36 M 36738 3.3 7.5 34.0 85.6 25.3 29.7 8600 P60L38E2 Normal 
Normocytic 
Normochromic Not done 12'15 9 20 35 5.2 2.1 3.1 3.4 2 1.4 40 32 78
25 46 M 37193 3.8 9.1 31 81.0 22.0 27.1 7200 P54L44E2 Normal 
Normocytic 
Hypochromic Not done 6'30 6 13 28 3.7 1.8 1.9 4.9 2.9 2 92 69 66
26 37 M 37205 3.9 9.5 33.0 115.2 38.8 34.1 12800 P78L21E1 Mod Macrocytosis Not done 8'3 5'30 11 24 5.6 2.7 2.9 1.6 0.8 0.8 96 67 109
27 48 F 37443 3.1 8.8 31 75.0 21.2 28.0 12200 P72L28E2 Normal 
Microcytic 
Hypochromic Normal 5'30 8 14 23 5.8 3 2.8 2.9 2.1 0.8 63 37 75
28 46 M 38197 3.5 7.6 31.0 87.6 27.6 31.7 6650 P54L43E3
Low 
Normal
Normocytic 
Normochromic Not done 8 5'30 18 24 6 3 3.0 1.6 1 0.6 61 46 86
29 39 M 38240 3.8 9.0 36 73.0 22.0 30.2 5600 P45L46E3M1 Normal 
Microcytic 
Hypochromic Not done 6'30 6'30 12 24 5.1 2 3.1 2.8 1.9 0.9 38 32 46
30 47 M 38348 3.6 7.5 44.0 88.6 26.1 29.0 3400 P45L46E3M1 Mod
Normocytic 
Normochromic Not done 4 6'15 13 26 4 1.9 2.1 3.2 2 1.2 69 87 63
31 49 F 39161 3.3 9.9 34 88.0 29.2 32.0 9200 P62L34E4 Normal 
Normocytic 
Normochromic 
Macronormo 
blast 3'30 7 14 26 5.7 2.7 3.0 1.9 1.2 0.7 43 33 67
32 49 M 39198 3.3 8.0 33.0 101 26.1 29.0 6700 P55L39E3
Low 
Normal Macrocytosis Not done 6 6'15 14 24 4.9 2.4 2.5 1.1 0.3 0.8 56 52 42
33 45 M 40085 3.6 10.2 38 85.4 25.4 29.2 5300 P40L46E14
Low 
Normal
Normocytic 
Hypochromic 
Macronormo 
blast 4 7 15 28 6 3 3.0 1.2. 0.8 0.4 56 52 69
34 55 F 40176 2.5 7.6 35.0 93 24.5 26.2 14000 P65L32E2
Low 
Normal
Normocytic 
Normochromic Not done 8'30 5'15 12 25 5.8 3 2.8 3.6 2 1.6 53 27 76
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35 42 M 40244 3.4 10.0 44 88.7 26.0 29.3 13500 P65L32E2
Low 
Normal 
Normocytic 
Normochromic 
Macronormo 
blasts 10'30 5 19 33 5.8 2.9 2.9 1.9 1 0.9 60 40 78
36 42 M 40286 3.1 8.0 34.0 88 29.5 31.0 12100 P46L46M4E2
Low 
Normal
Normocytic 
Normochromic Not done 4'30 5 14 30 6.3 3.1 3.2 2.8 1.7 1.1 52 34 98
37 55 M 40445 2.5 7.6 34 93.5 23.0 24.4 9200 P62L36E1M1 Normal 
Normocytic 
Normochromic 
Macronormo 
blasts 4 5'30 11 27 5.3 2.2 3.1 2.4 1.9 0.5 29 27 84
38 40 F 40650 3.6 10.0 31.0 77.6 26.1 33.6 9800 P70L28E2 Normal 
Microcytic 
Hypochromic Not done 8'15 6 16 24 5.2 2.5 2.7 2.4 1.8 0.6 61 47 74
39 42 M 41277 4.8 13.7 39 89.3 28.6 32.3 7200 P52L38E0
Low 
Normal 
Normocytic 
Normochromic Normal 8'3 8 17 26 6.1 3 3.1 3 3 0.4 29 38 46
40 51 M 41445 2.4 5.9 29.0 76 24.2 31.7 9400 P58L40E2 Mod
Microcytic 
Hypochromic Not done 8 6'45 14 26 4 2 2.0 2.4 1.2 1.2 62 47 66
41 47 M 43377 4.2 12.0 22 76.0 26.7 35.2 9000 P58L39E3
Low 
Normal 
microcytic  
Hypochromic
Micro normo 
blast 5 6'30 14 25 5.7 2.8 2.9 1.2 0.8 0.4 37 46 66
42 38 M 43465 4.0 10.1 37 85.0 26.6 30.2 12100 P72L28E0 Normal 
Normocytic 
Normochromic 
Erythroid 
Hyperplasia 5'45 5 17 23 5.4 2.5 2.9 3.2 2 1.2 30 22 62
43 33 M 43637 4.4 12.3 37 87.1 26.4 30.0 5900 P40L46E14
Low 
Normal 
Normocytic 
Hypochromic Normal 5'15 7'30 11 21 4.9 3 1.9 3.1 2.7 0.4 87 73 102
44 27 F 43677 2.7 10.1 34 79.0 26.2 33.1 9300 P58L40E2 Normal 
Normocytic 
Hypochromic Normal 6'45 9 16 21 5.9 2.9 3.0 3.2 2.2 1 29 33 59
45 41 M 43778 4.4 12.1 34 88.7 29.2 32.7 9300 P72L25E0  Normal
Normocytic 
Normochromic Normal 3'45 9'30 14 21 5.9 2 2.9 2.1 1 1.1 36 33 76
46 48 M 43982 3.8 9.6 33 88.0 30.6 28.1 2900 P49L45E4M2 Normal 
Normocytic 
Normochromic Normal 3'30 4 17 23 4.2 2 2.2 3.4 2.6 0.8 66 59 85
47 45 M 44498 5.0 13.3 34 93.0 23.0 24.2 6900 P58L40E2
Low 
Normal 
Normocytic 
Hypochromic Normal 9'30 7'30 16 27 3.7 1.7 2.0 4.8 2.8 2 92 70 92
48 23 M 44577 3.8 9.9 37 86.2 24.0 27.9 5700 P45L46E5M1 Normal 
Normocytic 
Hypochromic 
Erythroid 
Hyperplasia 5 6 14 25 3.8 1.8 2.0 2.2 1.5 0.7 74 59 75
49 53 M 44644 4.2 9.6 33 88.4 27.9 31.3 9300 P46L46E4E2
Low 
Normal 
Normocytic 
Normochromic 
Erythroid 
Hyperplasia 11 9 24 36 4.6 2 2.6 5.2 3.2 2 98 95 84
50 45 M 44737 3.7 10.1 32 109 32.3 29.3 17000 P78L21E1
Low 
normal
macrocytosis 
target cells Not done 4'0 5 16 22 5.8 3 2.8 1.6 1.2 0.4 38 27 73
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ABBREVIATIONS IN MASTER CHART 
BT - Bleeding Time  
CT - Clotting Time  
PT - Prothrombin Time  
APTT - Activated Partial thromoboplastin time  
MCH - Mean Corpuscular Hemoglobin 
MCHC - Mean Corpuscular Hemoglobin Concentration  
MCV - Mean Corpuscular Volume 
PCV - Packed cell volume 
UGD - Upper Gastro duodenal Endoscopy  
LFT - Liver function test 
AST - Aspartate transaminase 
ALT - Alanine transminase 
SAP - Serum Alkaline Phosphatase 
M - Male 
F - Female 
+ - Present 
- - Absent 
T - Total 
A - Albumin 
G - Globulin 
D - Direct 
I - Indirect 
Mod - Moderate 
